A Randomized Phase 2 Trial of Bortezomib–Dexamethasone Versus Bortezomib–Dexamethasone with Added Cyclophosphamide or Lenalidomide in Multiple Myeloma Patients Achieving Stable Disease After Four Cycles of Bortezomib–Dexamethasone Administered as Second-Line Treatment.
Meletios A Dimopoulos, Huw Roddie, Meral Beksaç, Lotfi Benboubker, Romualdas Jurgutis, Christian Langer, Javier de la Rubia, Luis Felipe Casado, Kazimierz Kuliczkowski, Lena Macukanovic-Golubovic, Thierry Façon (2009). A Randomized Phase 2 Trial of Bortezomib–Dexamethasone Versus Bortezomib–Dexamethasone with Added Cyclophosphamide or Lenalidomide in Multiple Myeloma Patients Achieving Stable Disease After Four Cycles of Bortezomib–Dexamethasone Administered as Second-Line Treatment.. , 114(22), DOI: https://doi.org/10.1182/blood.v114.22.4937.4937.
